JPRN-UMIN000031215已完成未知
Treatment of macular edema secondary to branch retinal vein occlusion with sub-tenon triamcinolone acetonide injection - Treatment of macular edema following BRVO with STTA
Aichi Medicak University Department of Ophthalmology0 个研究点目标入组 60 人开始时间: 2018年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The subject eye has retinal disease except BRVO. 2) Transparency of the subject eye is turbid. 3) Those who have active ocular infection or inactive toxoplasmosis. 4) Those who have glaucoma or ocular hypertension, or medical histories of them. 5) Those who have histories of herpetic infection in their subject eyes. 6) Those who have uncontrollable systemic disease. 7) Those who are systemic debility, or have severe heart disease, severe cerebral blood flow disorder or cirrhosis. 8) Serum creatinine is 2.0 mg/dL or more. 9) Those who have undergone vitreous surgery to the subject eye or who are expected to undergo vitreous surgery. 10) Those who have undertaken the following treatment within 24 weeks or who are expected to be undergone. Administration of corticosteroid to thesubject eye below the Tenon capsule or retro-bulbar. Intravitreal of drug to the subject eye. Administration of immunosuppressant drug, immunomodulatory drug, antimetabolites drug and/or alkylating agents. Hyperbaric oxygen therapy or stellate ganglion block. Hemodialysis or peritoneal dialysis. 11) Those who have received laser or intraocular surgery in the subject eye within 12 weeks or who are expected to undergo them. 12) Those who have received treatments which are corticosteroid, oral carbonic anhydrase inhibitor, warfarin, heparin, heparin analogue, selective thrombin inhibitor, direct thrombin inhibitors or(/and) FXa inhibitors within 4 weeks. Those who are expected to undergo these therapies. 13) Those who are planning of ophthalmic surgery during the observation period. 14) Those who have drug allergy to the drugs which are used in this study. 15) Those who cannot sufficient dilate pupil for inspection. 16) Pregnant or lactating women.
研究者
相似试验
进行中（未招募）
不适用
Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection - Ozurdex in post-occlusive macular edemamacular edema seconday to central or branch retinal vein occlusionMedDRA version: 13.1Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000425-72-ITIRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
招募中
4 期
Therapy of recalcitrant macular edema in aphakic and/or eyes with with severe iris-lens diaphragm disruption with longterm intravitreal steroid implants such as Iluvien® or Ozurdex®.recalcitrant macular edemaH35.8Other specified retinal disordersDRKS00020282Augenklinik des Klnikums der Ludwig-Maximilians-Universität München40
进行中（未招募）
1 期
Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®). - Lucentis in CRVOThis case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion.MedDRA version: 12.1Level: LLTClassification code 10007972Term: Central retinal vein occlusionMedDRA version: 12.1Level: LLTClassification code 10054467Term: Macular edemaEUCTR2009-017782-30-ATMedizinische Universität Graz, Universitäts-Augenklinik
已完成
1 期
Treatment of macular edema secondary to central vein occlusiocentral vein occlusion.Other retinal vascular occlusionsIRCT201011295270N1Banco de Olhos de Sorocaba15
进行中（未招募）
1 期
Treatment of Cystoid Macular Edema following cataract surgery. A randomized, double-masked, placebo-controlled, clinical trial. - Treatment of post-cataract CMEEUCTR2009-017031-18-NLRotterdam Eye Hospital25